Drugs / Clostridium difficile toxoid vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00772954 | Mar → Jun 2006 | Clostridium difficile colitis | Sanofi | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01896830 | Jul → Oct 2013 | Clostridium infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00772343 | Feb 2009 → Jul 2011 | Clostridium difficile colitis, diarrheal disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium difficile toxoid vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00772954 ↗ |
| Modality | Vaccine | “ACAM-CDIFF™ vaccine” NCT00772343 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscular on Days 0, 7, and 28” NCT00772343 ↗ |